<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00003852</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000067015</org_study_id>
    <secondary_id>FRE-FNCLCC-GETUG-04</secondary_id>
    <secondary_id>EU-99004</secondary_id>
    <nct_id>NCT00003852</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors</brief_title>
  <official_title>Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNICANCER</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNICANCER</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation
      may allow patients to tolerate higher doses of chemotherapy and kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy and peripheral
      stem cell transplantation in treating patients who have germ cell tumors that have not
      responded to previous chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the complete response rate (chemotherapy complete response,
      pathological complete response, or surgical complete response) to intensive chemotherapy with
      autologous peripheral blood stem cell support in patients with cisplatin resistant germ cell
      tumors. II. Determine duration of complete response and survival of these patients after this
      therapy. III. Determine the toxic effects of this regimen in these patients. IV. Determine
      the pharmacokinetics of this regimen and the relationship between these pharmacokinetics,
      nature and duration of response to treatment, and the toxic effects in these patients.

      OUTLINE: This is an open label, multicenter study. Patients receive epirubicin IV over 15
      minutes and paclitaxel IV over 3 hours on day 1, then filgrastim (G-CSF) subcutaneously (SQ)
      on days 5-14. Peripheral blood stem cells (PBSC) are collected on days 13 and 14. This course
      is repeated beginning on day 15. Patients then undergo a three part intensification regimen.
      Part I: Patients receive cyclophosphamide IV and thiotepa IV by continuous infusion on days
      34 and 35. PBSC are reinfused on day 38, and G-CSF SQ is administered from day 39 until blood
      cell counts recover. Part II: Patients receive etoposide IV over 2 hours, ifosfamide IV over
      4 hours, and carboplatin IV over 6 hours on days 62-66. PBSC are reinfused on day 70, and
      eventually G-CSF begins on day 71. Part III: Patients receive etoposide, ifosfamide, and
      carboplatin on days 90-94 as in part II. PBSC are reinfused on day 98 and eventually G-CSF
      begins on day 99. Patients are followed every month for the first year, every 2 months for
      the second year, every 6 months for the third and fourth years, then annually thereafter.

      PROJECTED ACCRUAL: A total of 45 patients will be accrued for this study within 2 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of patient inclusion
  </why_stopped>
  <start_date>March 1998</start_date>
  <completion_date type="Actual">March 2000</completion_date>
  <primary_completion_date type="Actual">March 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Childhood Germ Cell Tumor</condition>
  <condition>Extragonadal Germ Cell Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Testicular Germ Cell Tumor</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>epirubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>etoposide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ifosfamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>thiotepa</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bone marrow ablation with stem cell support</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically or cytologically proven germ cell tumor Seminoma or
        nondysgerminoma origin Gonadal (testicular or ovarian) OR Extragonadal OR Retroperitoneal
        OR Primitive mediastinal AFP elevated and/or HCG greater than 200 mIU/mL No growing
        teratoma Refractory disease to any treatment line Refractory disease is defined by the
        elevation of AFP and/or HCG during the chemotherapy Refractory to treatment line consisting
        of one conventional dose of cisplatin (dose intensity greater than 33 mg/m2/week) OR at
        least 1 month since last course of chemotherapy with or without increase in the size of
        measurable lesions OR Received 2 regimens of conventional chemotherapy, typically the
        following: Bleomycin, etoposide, and cisplatin: 3-4 courses* OR Etoposide and cisplatin: 4
        courses* AND Vinblastine, etoposide, ifosfamide, cisplatin: 4 courses of 3 week regimen (as
        standard salvage chemotherapy)* * Unless patients could be treated with a first line
        conventional treatment OR a first salvage conventional treatment especially patients who
        could be treated with T93 good prognosis protocol or T93 bad prognosis protocol or IT94
        protocol Bidimensionally measurable disease OR Significant elevation of tumor markers: HCG,
        free beta-HCG, AFP OR Evaluable disease plus increase in tumor markers No germ cell CNS
        tumors or clinically significant CNS metastases

        PATIENT CHARACTERISTICS: Age: Over 15 Performance status: ECOG 0-2 Life expectancy: Greater
        than 3 months Hematopoietic: WBC greater than 3,000/mm3 AND Platelet count greater than
        150,000/mm3 Hepatic: Bilirubin less than 1.5 times normal SGOT/SGPT less than 2 times upper
        limit of normal (ULN) Alkaline phosphatase less than 2 times ULN Gamma glutamyl transferase
        less than 2 times ULN Renal: Creatinine less than 1.4 mg/dL Creatine clearance greater than
        60 mL/min Cardiovascular: No cardiac insufficiency LVEF at least 50% Other: HIV negative No
        other malignancy except basal cell skin cancer

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No prior intensive chemotherapy with stem cell support Endocrine therapy:
        Not specified Radiotherapy: Prior prophylactic anterior irradiation of the diaphragm for
        stage I seminoma allowed Surgery: Not specified
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Biron, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Leon Berard</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Paul Papin</name>
      <address>
        <city>Angers</city>
        <zip>49036</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Besancon - Hopital Jean Minjoz</name>
      <address>
        <city>Besancon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonie</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional Francois Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Lute Contre le Cancer,Georges-Francois Leclerc</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHR de Grenoble - La Tronche</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Michel</name>
      <address>
        <city>La Rochelle</city>
        <zip>17000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut J. Paoli and I. Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Regional de Lutte Contre le Cancer - Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital d'Instruction des Armees du Val de Grace</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Jean Godinot</name>
      <address>
        <city>Reims</city>
        <zip>51056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Rene Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92211</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaire de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>F-94805</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>January 26, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2004</study_first_posted>
  <last_update_submitted>June 22, 2016</last_update_submitted>
  <last_update_submitted_qc>June 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 23, 2016</last_update_posted>
  <keyword>recurrent malignant testicular germ cell tumor</keyword>
  <keyword>childhood germ cell tumor</keyword>
  <keyword>recurrent ovarian germ cell tumor</keyword>
  <keyword>extragonadal germ cell tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Germ Cell and Embryonal</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Ifosfamide</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

